UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice

Virology (New York, N.Y.), 2024-10, Vol.598, p.110194, Article 110194

2024

Volltextzugriff (PDF)

Development of innate and adaptive immunity to RSV in young children

Cellular immunology, 2024-05, Vol.399-400, p.104824, Article 104824

2024

Volltextzugriff (PDF)

Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy

The New England journal of medicine, 2022-04, Vol.386 (17), p.1615-1626

2022

Volltextzugriff (PDF)

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.e637-e646

2024

Volltextzugriff (PDF)

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

The Journal of infectious diseases, 2017-12, Vol.216 (11), p.1362-1370

2017

Volltextzugriff (PDF)

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.e647-e656

2024

Volltextzugriff (PDF)

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

The Lancet infectious diseases, 2016-08, Vol.16 (8), p.e153-e163

2016

Volltextzugriff (PDF)

Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus

Frontiers in immunology, 2024-06, Vol.15, p.1376395

2024

Volltextzugriff (PDF)

Investigational RSV Vaccine Given During Pregnancy Protects Newborns

JAMA : the journal of the American Medical Association, 2022-12, Vol.328 (22), p.2201

Larkin, Howard

2022

Volltextzugriff (PDF)

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Clinical infectious diseases, 2024-05, Vol.78 (5), p.1360-1368

2024

Volltextzugriff (PDF)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Antimicrobial agents and chemotherapy, 2016-01, Vol.60 (1), p.6-13

2016

Volltextzugriff (PDF)

Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial

The Journal of infectious diseases, 2024-08, Vol.230 (2), p.e374-e383

2024

Volltextzugriff (PDF)

Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination

The Journal of infectious diseases, 2024-10, Vol.230 (4), p.e905-e916

2024

Volltextzugriff (PDF)

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

The Journal of infectious diseases, 2020-02, Vol.221 (4), p.534-543

2020

Volltextzugriff (PDF)

Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants

Vaccine, 2020-01, Vol.38 (2), p.251-257

2020

Volltextzugriff (PDF)

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

The Journal of infectious diseases, 2017-01, Vol.215 (1), p.24-33

2017

Volltextzugriff (PDF)

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

The Journal of infectious diseases, 2024-07, Vol.230 (1), p.e102-e110

2024

Volltextzugriff (PDF)

Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective

Journal of virology, 2017-05, Vol.91 (10)

2017

Volltextzugriff (PDF)

Passive and active immunization against respiratory syncytial virus for the young and old

Expert review of vaccines, 2017-07, Vol.16 (7), p.737-749

2017

Volltextzugriff (PDF)

VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice

Vaccine, 2024-05, Vol.42 (15), p.3474-3485

2024

Volltextzugriff (PDF)

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Immunity (Cambridge, Mass.), 2021-04, Vol.54 (4), p.769-780.e6

2021

Volltextzugriff (PDF)

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Clinical infectious diseases, 2024-10, Vol.79 (4), p.1088-1098

2024

Volltextzugriff (PDF)

Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18–49 years of age: Results of a randomized phase 3 study

Vaccine, 2024-05, Vol.42 (13), p.3172-3179

2024

Volltextzugriff (PDF)

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

Clinical infectious diseases, 2024-08, Vol.79 (4), p.1074-1084

2024

Volltextzugriff (PDF)

The CD4 T cell response to respiratory syncytial virus infection

Immunologic research, 2014-08, Vol.59 (1-3), p.109-117

2014

Volltextzugriff (PDF)

1 – 25 von 2.357

Suche als RSS-Feed

Aktive Filter

KollektionNature_系列刊

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.244)
Mit Volltextzugriff
(1.805)

Publikationsform

Sprache

11 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.143)
Life Sciences & Biomedicine
(2.053)
Humans
(1.821)
Respiratory Syncytial Virus
(1.502)
Male
(1.483)
Immunology
(1.285)
Infant
(1.035)
Infectious Diseases
(917)
Animals
(864)
Respiratory Syncytial Virus Infections - Immunology
(789)
Biological And Medical Sciences
(782)
Child, Preschool
(652)
Respiratory Syncytial Viruses - Immunology
(640)
Medical Sciences
(602)
Microbiology
(601)
Mice
(587)
Infant, Newborn
(542)
Mice, Inbred Balb C
(531)
Virology
(490)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.356)
Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
(1.463)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(1.192)
IngentaConnect
(1.139)
Single Journals
(887)
IngentaConnect Journals
(597)
ScienceDirect Journals (5 years ago - present)
(512)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(456)
Oxford Journals Current Collection
(327)
Oxford Journals 2020 Medicine
(302)
Wiley Blackwell Single Titles
(288)
JSTOR Archive Collection A-Z Listing
(283)
Wiley Online Library Full Collection 2018
(225)
Springer Online Journals Complete
(104)
Taylor & Francis Journals Auto-Holdings Collection
(65)
Taylor & Francis
(65)
Taylor & Francis:Master (3349 titles)
(60)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(51)
BMJ Journals
(43)
BMJ Journals Archiv - DFG Nationallizenzen
(26)
Nature Journals Online
(0)

16 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(18)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice

Development of innate and adaptive immunity to RSV in young children

Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus

Investigational RSV Vaccine Given During Pregnancy Protects Newborns

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial

Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective

Passive and active immunization against respiratory syncytial virus for the young and old

VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18–49 years of age: Results of a randomized phase 3 study

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

The CD4 T cell response to respiratory syncytial virus infection

Aktive Filter

Suchergebnisse filtern